Nogo-A, an axonal growth inhibitory protein known to be mostly present in CNS myelin, was upregulated in retinal ganglion cells (RGCs) after optic nerve injury in adult mice. Nogo-A increased concomitantly with the endoplasmic reticulum stress (ER stress) marker C/EBP homologous protein (CHOP), but CHOP immunostaining and the apoptosis marker annexin V did not co-localize with Nogo-A in individual RGC cell bodies, suggesting that injury-induced Nogo-A upregulation is not involved in axotomyinduced cell death. Silencing Nogo-A with an adeno-associated virus serotype 2 containing a short hairpin RNA (AAV2.shRNANogo-A) or Nogo-A gene ablation in knock-out (KO) animals had little effect on the lesion-induced cell stress or death. On the other hand, Nogo-A overexpression mediated by AAV2.Nogo-A exacerbated RGC cell death after injury. Strikingly, however, injury-induced sprouting of the cut axons and the expression of growth-associated molecules were markedly reduced by AAV2.shRNA-Nogo-A. The axonal growth in the optic nerve activated by the intraocular injection of the inflammatory molecule Pam3Cys tended to be lower in Nogo-A KO mice than in WT mice. Nogo-A overexpression in RGCs in vivo or in the neuronal cell line F11 in vitro promoted regeneration, demonstrating a positive, cell-autonomous role for neuronal Nogo-A in the modulation of axonal regeneration.
The membrane protein Nogo-A is one of the best characterized myelin-derived inhibitors for neurite outgrowth. 1 The blockade of Nogo-A or its receptor or the systemic deletion of Nogo-A in knock-out mice (KO) enhanced axonal plasticity in the injured spinal cord and improved motor function recovery. 2, 3 After optic nerve crush, the blockade of Nogo-A or cognate molecules enabled retinal ganglion cell (RGC) axons to regrow, but only to a limited extent. [4] [5] [6] The stimulation of the neuronal growth program by inflammatory molecules such as the toll-like receptor 2 agonists zymosan or Pam3Cys had a somewhat stronger effect on optic axon regeneration. [7] [8] [9] The inhibition of the Nogo-A receptor NgR1 or its down-stream mediator Rho-A exerted synergistic effects on optic axon regrowth when combined with inflammatory molecules. 4, 10 However, recent studies also suggested that the intrinsic growth capacity of the injured retinal neurons as well as their responsiveness to external growth factor stimulation are impaired after axonal injury; after optic nerve lesion, increased levels of phosphatase and tensin homolog (PTEN) and tuberous sclerosis complex 1 (TSC1) inhibited the mammalian target of rapamycin (mTOR)-dependent protein synthesis. 11 In addition, the responsiveness of RGCs to Ciliary Neurotrophic Factor (CNTF) was reported to be compromised by the intracellular upregulation of suppressor of cytokine signaling 3 (SOCS3), a negative regulator of the Janus Kinase 3/Signal Transducer and Activator of Transcription 3 (Jak3/Stat3) pathway. 12 Although Nogo-A occurs mostly in oligodendrocytes in the adult CNS, subtypes of neurons also express the protein, but its function in these cells is unknown. Here, we found that the neuronal content of Nogo-A was increased in RGC neurons after optic nerve injury, similar to results recently described for cortical and thalamic neurons after stroke. 13, 14 This opens the possibility that neuronal Nogo-A may have a role in the cell death/survival and/or regeneration response of injured CNS neurons.
14 Interestingly, the genetic deletion of Nogo-A/B in mutant mice worsened the motor and cognitive deficits after traumatic brain injury and accelerated the degeneration of motorneuron axons in a model of amyotrophic lateral sclerosis (ALS). [14] [15] [16] A neuroprotective effect of Nogo was proposed to be related to an attenuation of endoplasmic reticulum (ER) stress. 15 Only few and contradictory observations are available on such a role of Nogo (reticulon 4 (RTN4)) or other RTN proteins, and they rely mostly on in vitro or overexpression experiments. 15, [17] [18] [19] [20] [21] We therefore investigated axonal regeneration and survival of RGCs after optic nerve crush in mice with systemic Nogo-A deletion (KO) or neuron-specific knock down using adeno-associated virus vector of serotype 2 (AAV2) that selectively infect RGCs in the retina. For the first time, our work demonstrates that the exogenous increase of neuronal Nogo-A driven by AAV2.Nogo-A, but not the endogenous upregulation of neuronal Nogo-A because of axonal damage enhanced RGC cell loss. Our results also reveal a positive function for neuronal Nogo-A on the intrinsic growth properties of damaged neurons.
Results
Nogo-A is specifically upregulated in RGCs after axotomy. In the intact retina of adult mice Nogo-A was detected by immunofluorescence almost exclusively in Mü ller cells; in freshly isolated Mü ller cells the protein was localized in the inner processes of the Mü ller glia (end-feet) (Figures 1a and b) . The protein Nogo-B, a small splice form of Nogo-A, was similarly concentrated in Mü ller cell extensions (data not shown). After axotomy, Nogo-A remained unchanged in the glial end-feet, whereas the gliosis marker Glial Fibrillary Acidic Protein (GFAP) was strongly upregulated and spread apically in the radial processes of the Mü ller cells (Figures 1c and d) . The Figure S2A -C). When we compared WT and Nogo-A KO retinae by semi-qRT-PCR at 5 days post-injury, the mRNA upregulation of vimentin and GFAP, two indicators of gliosis, did not differ between KO and WT retinae (Figures 1f and g ). This suggests that the bulk part of Nogo-A in the retina is constitutively expressed by the Mü ller glia and is not influenced by axotomy, in contrast to the cytoskeletal proteins. To obtain a higher resolution of the localization of Nogo-A we analyzed retinal flat-mounts in the layer of the RGCs by confocal microscopy (Figures 2A and B) . In the intact retina, Nogo-A appeared mostly in the end-feet of the Mü ller cells (EF, Figure 2a -a 000 ) and in a few b3Tubulin-labeled RGC cell bodies (Figure 2a 000 , arrowhead). In lesioned retinae, however, Nogo-A dramatically increased in some RGCs (Figure 2b 000 , arrowheads), whereas other RGCs did not contain Nogo-A at a detectable level ( Figure  2b 000 , arrow). Quantitatively, Nogo-A was detected in B15% of RGCs in the intact retina and rose to B55% of the surviving RGCs 7 or 14 days post-lesion ( Figure 2C ). In the superior quadrant, the measurement of the mean soma diameter revealed that Nogo-A-expressing neurons were bigger than RGCs whose cell bodies did not contain Nogo-A ( Figure 2D) . A large majority of RGCs whose somata exceeded 13 mm in diameter expressed Nogo-A after injury ( Figures 2E-H) . Strikingly, in contrast to Nogo-A, Nogo-B was never observed in intact or injured RGCs (Supplementary Figure S3) . The long-lasting upregulation of Nogo-A in injured RGCs points to a particular role for this RTN isoform in the neuronal response to injury.
The ER stress response and apoptotic cell death occur concomitantly with Nogo-A upregulation but not in the same cells after axonal injury. So far, the ER stress activation was not studied after axonal injury. As Nogo-A belongs to the RTN family, which is especially enriched in the ER, we wondered whether neuronal Nogo-A upregulation could reflect the activation of the ER stress response. By semi-qRT-PCR, the pro-apoptotic transcription factors C/EBP homologous protein (CHOP)/GADD153 and c-Jun increased as early as 1 day and peaked at 3 days postaxotomy (Figure 3a) . The increase of CHOP/GADD153 protein was confirmed at 3 and 5 days post-lesion by western blotting (Figure 3c, Supplementary Figure S2D) . Upstream of CHOP, the active phosphorylated-eIF2a protein was detected in RGCs 3 days after axotomy (Figure 3b) , suggesting that the eIF2a/CHOP pathway is stimulated by the optic nerve lesion. Accordingly, on retinal sections, the CHOP/GADD153 protein was strongly increased in the (Figure 3d ). Among the different members of the activating transcription factor (ATF) family, only ATF3 was found to be upregulated in agreement with a previous study (Figures 3a and 6g ).
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The relationship between neuronal Nogo-A upregulation, ER stress and neuronal cell death was then analyzed by double immunofluorescence stainings for Nogo-A and CHOP/ GADD153 or the apoptosis marker annexin V, respectively (Figures 3e and f) . On 5-day post-axotomy retinal flat-mounts, the large soma-sized RGCs labelled for Nogo-A exhibited a weak or no signal for CHOP/GADD153 (Figure 3e ). As the contribution of CHOP/GADD153 to the process of RGC apoptosis is not known, we intraocularly injected annexin V, a protein binding to the cell membrane in the early stage of apoptosis. 23 For all retinal quadrants, Nogo-A could not be detected in the annexin V-positive neurons, showing that the injury-induced Nogo-A increase is not correlated with cell death (Figure 3f ). Nevertheless, it remains possible that in small RGC cells, where Nogo-A was much weaker than in large sized RGCs, Nogo-A was downregulated right before apoptosis and therefore was below the level of detection by immunohistochemistry.
Overexpression but not endogenous Nogo-A up-regulation influences RGC cell loss after optic nerve lesion. To directly address the influence of Nogo-A on the ER stress activation and RGC apoptosis, Nogo-A was down-or upregulated using AAV2 containing a short hairpin RNA (shRNA) or the gene sequence for Nogo-A, respectively ( Figure 4 ). AAV2 preferentially infects neurons and showed a high selectivity for RGCs in the retina. 24 By semi-qRT-PCR Two weeks after optic nerve transection, the density of surviving neurons as evaluated by staining RGCs for b3Tubulin on retinal flat-mounts was decreased by 75% ( Figure 5 ) compared with intact retinae (Supplementary Figure S4C ). In the whole retina, the average density of surviving RGCs was not significantly changed neither by Nogo-A knock down nor by Nogo-A overexpression compared with the group receiving AAV2.GFP or the untreated animals ( Figure 5a ). The intraocular injection of AAV2 viruses in the superior retinal quadrant could produce a higher rate of infection in this region possibly leading to stronger effects on survival. 24 The density of surviving RGCs was therefore separately examined in this part of the retina. Interestingly, in the superior quadrant of the retina, animals infected with AAV2.Nogo-A presented a significantly higher axotomy-induced loss of RGCs at 14 days than any other group ( This suggests that the ectopic expression of Nogo-A may exacerbate cell death in cells that have a low endogenous expression of Nogo-A, whereas the majority of large cells upregulating Nogo-A after injury seemed unaffected.
The silencing of Nogo-A with AAV2.shRNA-Nogo-A did not significantly change the CHOP/GADD153 mRNA levels post-lesion when compared with AAV2.GFP-treated retinae (Supplementary Figure S4A) . A slight elevation of CHOP/ GADD153 mRNA was, however, noticed in the group treated with AAV2.Nogo-A (Supplementary Figure S4A) . In addition, the mRNA level of CHOP/GADD153 was not differentially upregulated in Nogo-A KO and WT retinae 5 days after injury (Supplementary Figure S4B) . Consistent with that, the number of RGCs was not much different between WT and Nogo-A KO retinae (Supplementary Figure S4C) . These results indicate that axotomy-induced Nogo-A upregulation occurs concomitantly but independently of ER stress activation after optic nerve transection.
Neuronal Nogo-A contributes to the axonal growth response in RGCs. Axonal regeneration was examined 2 weeks after optic nerve crush and neuronal Nogo-A silencing with AAV2.shRNA-Nogo-A. A limited number of axonal fibers was consistently observed in the distal part of the injured optic nerves in absence of treatment or after AAV2.GFP or AAV2.shRNA-luciferase injections (Figures 6a and b) . In those respective control nerves, a mean of 58.8±5.7 axons or 58.1±12 axons per optic nerve were counted at 100 mm (Figure 6d ). At the same distance, animals injected with AAV2.shRNA-Nogo-A showed much less axonal sprouting across the lesion site (4.4±2.5 axons/ optic nerve) (Figures 6a-d) . The injury-induced growth response of RGCs was further analyzed by following gene expression changes of Sprr1A, GAP-43 and ATF3, three important regulators of axonal regeneration in the CNS and the PNS. 25, 26 The three growth marker mRNAs increased quickly after injury and peaked at 3-5 days post-optic nerve transection (data not shown). Silencing neuronal Nogo-A in injured retina with AAV2.shRNA-Nogo-A lowered the induction of Sprr1A, GAP-43, and ATF3 mRNA (Figures 6e-g ; analysis of variance (ANOVA); *Po0.05; **Po0.01). Over-expressing Nogo-A by the administration of AAV2.Nogo-A did not disturb the injuryinduced increase of the three growth markers used (data not shown). These data indicate that neuronal Nogo-A upregulation consecutive to axotomy seems to positively influence or contribute to the neuronal growth response.
Neuronal Nogo-A deletion in Nogo-A KO mice alters RGC responsiveness to growth stimulation. We then investigated how the complete deletion of glial and neuronal Nogo-A in Nogo-A KO mice affected axonal regeneration. Two weeks after injury, the number of axons growing at 100, 250, 500 and 1000 microns past the lesion site in Nogo-A KO mice appeared very similar to that of WT mice ( Figure 7A ). This could mean that the systemic deletion of Nogo-A is not sufficient to promote axonal outgrowth. To place the injured RGCs in an enhanced growth mode, we injected the inflammatory agent Pam3Cys in the vitreous body of lesioned animals. 9 Injecting Pam3Cys in the vitreous space of C57BL/6 mice strongly activated axonal regrowth in the optic nerve ( Figures 7A and C) . In Nogo-A KO optic nerves, however, the density of growing axons tended to be lower than in WT animals ( Figures 7A, C and D) . To evaluate the contribution of neuronal Nogo-A to the axonal growth observed in Nogo-A KO animals, AAV2.Nogo-A was injected 4 weeks before lesion. The growth stimulation with Pam3Cys in this group induced many more growing axons than in Nogo-A KO mice ( Figures 7B, D and E) . In contrast, the control virus AAV2.GFP did not influence the number of regenerating fibers in WT individuals treated with Pam3Cys (data not shown). Thus, the forced expression of Nogo-A in RGC neurons can modulate the axonal growth triggered by intraocular inflammation.
Interestingly, the transcript levels of the Nogo-A receptor components NgR1 and Lingo1 were downregulated by the optic nerve lesion, suggesting that RGCs may be desensitized to myelin inhibitors after injury (Supplementary Figures  S5A-B) . However, expression changes after lesion did not differ between Nogo-A KO and WT animals. In addition, the gene expression of the pro-apoptotic cytokine TNFa and of survival factors FGF2, CNTF, LIF and BDNF were similarly upregulated in the axotomized retinae of Nogo-A KO and WT mice (Supplementary Figures S5C-D) .
Nogo-A levels influence neurite growth in isolated neuronal cells. To assess whether the effects of neuronal Nogo-A on neurite outgrowth were cell-autonomous, Nogo-A was modulated with AAV in the dorsal root ganglia-derived neuronal cell line F11 cultured at single cell density. The levels of Nogo-A were observed by immunocytochemistry in single cells after AAV treatment and forskolin-induced neurite Figure 6 Silencing Nogo-A in RGCs reduces the neuronal growth response and axonal sprouting in the optic nerve. To study axonal regeneration in the crushed optic nerve, AAV2 vectors were injected 4 weeks before injury and growing axons were traced by injecting intraocularly the cholera toxin-b subunit coupled to alexa 594 (CTb-594) the day preceding the killing. Axonal regeneration was analyzed on longitudinal sections at 100 mm past the lesion site. (a and b) Two weeks after injury, a small number of axons had crossed the lesion site (dark arrowheads) in the optic nerves of untreated mice and of those receiving the control viruses AAV2.GFP or AAV2.shRNA-Luciferase. (c) Almost no axons were able to extend in the distal optic nerve of mice treated with AAV2.shRNA-Nogo-A (right-hand side). (d) Quantitatively, the number of axonal fibers growing across the lesion site was statistically lower after AAV2.shRNA-Nogo-A injection than in groups treated with AAV2.GFP, AAV2.shRNA-luciferase or uninjected (mean±S.E.M., ANOVA, Dunnett's post hoc test, *Po0.05, **Po0.01). (e-g) The mRNAs of growth-associated protein Sprr1A, GAP-43 and ATF3 were decreased by AAV2.shRNA-Nogo-A compared with mice administered with AAV2.GFP or those let untreated (ANOVA, *Po0.05, **Po0.01). Note that the overexpression of Nogo-A with AAV2.Nogo-A had no effects on the expression of growth-related proteins (data not shown). Scale bar: A inset ¼ 100 mm outgrowth (Figures 8a-c) . The expression of GFP with control virus did not influence the intensity of Nogo-A staining (Figure 8a) . Transfecting F11 cells with Nogo-A shRNA strongly repressed Nogo-A expression (Figure 8b ). In contrast, the level of Nogo-A was increased in a way that was tightly correlated with the expression of the His-tag reporter after the addition of AAV2.Nogo-A (Figure 8c ). AAV2.GFP or AAV8.GFP did not significantly change neurite outgrowth relative to forskolin treatment alone (Figures 8d, m) . The knock down of Nogo-A with AAV8.shRNA-Nogo-A caused a statistically significant decrease (27%) in neurite outgrowth compared with the AAV8.GFP group (Figure 8d-i and m; ANOVA, *Po0.05). Inversely, the upregulation of Nogo-A significantly increased the length of F11 neurites by 47% (Figures 8j-m Figure S6) . The direct correlation between Nogo-A expression and neurite extension supports a cellautonomous and positive effect of Nogo-A on neurite outgrowth.
Discussion
Following injury to the optic nerve of adult mice, Nogo-A was rapidly and selectively upregulated in RGCs. Although a pronounced ER stress response was induced by the optic nerve axotomy, we could not find a correlation with the accumulation of Nogo-A in RGC cell bodies. The experimental overexpression or downregulation of Nogo-A did not change the survival of lesioned RGCs. In contrast, the regenerative growth response and axonal sprouting were diminished in Nogo-A KO animals and in WT mice where neuronal Nogo-A was downregulated by shRNA transfection. Neuronal Nogo-A modulates axonal regeneration V Pernet et al Surprisingly, Nogo-A was found in three different cell types in the adult retina and optic nerve: oligodendrocytes, as expected from many other regions of the CNS, a subtype of neuron that is, the RGC after injury, and Mü ller cells. In the adult retina, the Mü ller glia was the main cell type producing Nogo-A and Nogo-B. The polarized distribution of Nogo-A and B in the inner Mü ller end-feet resembled that of RTN 3 or the myelin protein MAG. 27, 28 As for those two other proteins, the physiological role of Nogo-A and -B in the Mü ller cells is not known. Mü ller cells react massively to RGC axotomy and have a key role in the inflammatory mechanisms, activating axonal regeneration in the optic nerve after injury, presumably by releasing trophic factors such as CNTF. 8, 29 However, Nogo-A levels remained unchanged after optic nerve lesion in the Mü ller glia and the loss of Nogo-A in the Mü ller cells in the KO mice did not modify the axotomy-induced gliosis.
Although cell surface Nogo-A is well known to exert growth inhibitory effects on neighboring cells via a specific Nogo-A receptor complex, the functions of the high levels of intracellular Nogo-A, in particular in neurons, are largely unknown. As cell death is massive after axotomy in the RGC population of the retina, we studied a possible function of neuronal Nogo-A in RGC apoptosis. Surprisingly, Nogo-A did not contribute at a significant degree to either survival or apoptosis and ER stress. The elevation of CHOP/GADD153 in injured RGCs was not correlated with the increase of Nogo-A, contrary to what was demonstrated for RTN3 in HeLa cells in culture. 20 Furthermore, neither overexpression nor downregulation of Nogo-A with AAV2 vectors changed significantly the level of CHOP/GADD153 in the retinae. This is consistent with a recent study showing that transfecting COS-7 cells with different RTN proteins did not elicit the activation of CHOP/GADD153 in vitro. 15 In contrast, RTN1C over-expression in cortical neurons caused the elevation of CHOP/GADD153 and Bip associated with apoptotic death in vivo.
19 RTN proteins may thus exert opposite effect on the expression of ER stress proteins and the survival of cells. Concerning Nogo-A, the protein was not detectable in apoptotic RGCs labelled with annexin V, and the downregulation of Nogo-A had no global effect on RGC survival. Axotomy-induced Nogo-A upregulation is therefore unlikely to have a major role in neuronal apoptosis in the retina. However, AAV2-mediated Nogo-A downregulation caused less cell death than the overexpression with AAV2.Nogo-A vector, especially in the superior quadrant of the retina. In addition, we did observe that ectopic expression of Nogo-A with AAV2.Nogo-A exacerbated cell death and induced axonal swelling in some neurons, where the infection was 
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The situation in the retina therefore also differs from a model of ALS, where the ablation of the Nogo-A/B gene accelerated the degeneration of ventral motor neuron axons, 15 whereas the systemic absence of Nogo-A slowed the disease, and Nogo-A overexpression in muscle enhanced neuromuscular endplate degeneration. 30 Recent studies showed that the neutralization of Lingo or NgR1, 2 receptor components for Nogo-A, promoted RGC survival after optic nerve transection. Therefore, we cannot exclude that the Nogo receptor complex mediates some of the death promoting effects observed after increasing Nogo-A in neuronal cells. 31, 32 Although a majority of RCGs die within 1-2 weeks after optic nerve lesion, the remaining, mostly large diameter neurons show regenerative sprouting and upregulation of growth markers. 33, 34 The increase of Nogo-A especially in these large cells may have a role in the neurite regeneration of RGCs. Nogo-A may be required, although it was not sufficient to confer a higher intrinsic growth capacity to this subset of neurons. Thus, optic axon sprouting was reduced and the lesion-induced increase of Sprr1A, GAP-43 and ATF3 mRNAs was attenuated after neuronal Nogo-A silencing. In turn, the forced expression of Nogo-A in RGCs rescued the decreased axonal regeneration in Nogo-A KO optic nerves treated with Pam3Cys. In isolated F11 cells, the expression of Nogo-A clearly influenced the neuritic length in a positive fashion, suggesting a cell-autonomous effect of Nogo-A on neuronal growth. The exact mechanism is not clear but one may speculate that ER-associated Nogo-A contributes to maintain the neuronal homeostasis by preserving ER structure, protein synthesis and intracellular transport, all processes required for axonal growth and regeneration.
In the present study, Nogo-A KO optic nerve axons did not regenerate better than WT nerves. This result is in contrast with the weaker neurite sprouting that we observed after acute blockade of Nogo-A upregulation with AAV2.shRNA treatment and could be explained by compensatory mechanisms occurring in Nogo-A KO animals. However, earlier studies showed increased axonal regeneration in the optic nerve after blocking Nogo-A with the neutralizing antibody IN-1 secreted by hybridoma cells combined with FGF2 or CNTF. 6, 35 These results are in line with the regeneration enhancement found for corticospinal axons in Nogo-A KO mice after spinal cord lesion and indicate that the inactivation of Nogo-A at the cell surface is beneficial for optic axon growth in vivo.
3 In Nogo-A KO mice, the better responsiveness in the corticospinal tract could be because of differences in the intrinsic growth ability between RGCs and cortical neurons or to the severity of the lesion. For example, RGCs die massively after optic nerve crush, whereas spinal cord injury causes a slow shrinkage of the cortical neurons without significant cell death. 36 Administration of Nogo-A blocking antibodies appears, therefore, as a good strategy to relieve the neurite growth inhibition caused by oligodendrocyte/myelin Nogo-A, without affecting intracellular neuronal Nogo-A.
In summary, our results show for the first time that, in vivo, Nogo-A upregulation in neurons does not take part to ER stress-associated apoptosis, but positively influences the growth response after axonal injury.
Materials and Methods
Animals. All surgeries were performed on 2-4 month old male C57BL/6 mice. Animal experiments were performed in accordance with the guidelines of the Veterinary Office of the Canton of Zurich. As previously described, Nogo-A KO mice were generated by homologous recombination of exons 2 and 3 in Nogo-A gene in a C57BL/6 background. 2 The transgenic strain was routinely genotyped by PCRs using the following primer sequences:
AAV vector production. The recombinant pAAV-EGFP construct was generated by inserting the enhanced green fluorescent protein cDNA into the XhoI and BglII restriction sites in pAAV-MCS (Stratagene, La Jolla, CA, USA). For pAAV-shNogo856, three different siRNA sequences targeted against the amino portion of Nogo-A were screened for efficiency in vitro. Antisense-loop-sense oligonucleotides corresponding to nucleotides 856-874 of rat Nogo-A cDNA sequence (shNogo856) were synthesized, annealed and subcloned into the Bbs1 and Xba1 sites of the mU6pro plasmid as described. 37 The U6-shNogo856 fragment was then inserted into the pAAV-EGFP plasmid at the MluI site upstream of the CMV promoter. The control hairpin siRNA, shLuc, targeted against photinus pyralis luciferase, was constructed by annealing and inserting the described oligonucleotides into the BamH1/EcoR1 sites on the pZac2.1-U6-luc-CMVZsgreen. The pAAV2.Nogo-A construct was generated by inserting the full length of the rat Nogo-A gene sequence between the BamH1 and SnaB1 sites in the pAAVcmv(0.3)nlsLacZ plasmid. All plasmids were verified by sequencing and purified by Maxiprep (Qiagen, Hilden, Germany).
Adeno-associated viral vectors were produced by standard methods. Briefly, triple plasmid co-transfection method 38 was used with the plasmids described above. After purification by an iodixanol step gradient, the fraction containing the virus was either loaded onto a Hi-Trap Q-HP 1 ml heparin column (GE Healthcare, Chalfont St. Giles, UK) for column purification or directly concentrated and desalted on 100 K concentrators with PBS as the diluent. Vectors were then titered for DNase-resistant vector genomes by Real-Time qPCR relative to standards or by dot blot assay.
Vector concentrations were calculated in genomes/ml with AAV8.GFP at 1.3 Â 10 13 vg/ml, AAV8.shRNA-Nogo-A at 1.3 Â 10 13 vg/ml, AAV2.GFP at 2.8 Â 10 13 vg/ml, AAV2.shRNA-Nogo-A at 2.6 Â 10 13 vg/ml, AAV2.shRNA-Luciferase at 2.4 Â 10 13 vg/ml and AAV2.Nogo-A at 5.1 Â 10 11 vg/ml. The quantification of GFP positive cells allowed to determine that B71% of RGCs were infected by AAV2.shRNA-Nogo-A. By counting the number of His-tag-labeled RGCs, the rate of cells infected by AAV2.Nogo-A represented B40%. In vitro, the addition of AAV8.shRNA-Nogo-A diminished selectively the Nogo-A protein level in the RGC-5 cell line without affecting Nogo-B, thereby demonstrating the specificity of the construct for Nogo-A. Neither AAV2.Nogo-A nor AAV2.shRNA-Nogo-A affected the number of RGCs in intact retinae; the viruses were therefore not toxic by themselves.
Neuronal survival. The survival of RGCs was assessed after intraorbital optic nerve axotomy. Under general anesthesia, the optic nerve was exposed at B0.5 mm from the back of the eye without damaging the ophthalmic artery. In all, 2 weeks after injury the animals were intracardially perfused with 4% paraformaldehyde (PFA). The retinae were flat-mounted on a glass slide and placed onto a small piece of Whatman filter paper for an overnight post-fixation in 4% PFA at 4 1C. The RGCs were visualized by immunostaining for b3Tubulin on retinal flat-mounts. The retinae were intensively washed with PBS and incubated with the primary antibody in a solution of PBS containing 0.3% of Triton-X-100, 5% of normal serum and 0.05% sodium azide for 10-14 days at 4 1C. Then, after washings the retinae were incubated for 3 days with a goat anti-mouse secondary antibody coupled to alexa 594 or Cy3 at 4 1C. The b3Tubulin-positive RGCs were imaged in the four quadrants of the retina using a Spectral Confocal Microscope TCS SP2 AOBS (Leica, Heerbrugg, Switzerland) with a Â 40 oil immersion objective (HCX PL APO 1.25-0.75 oil CS). Image stacks were acquired in the ganglion cell layer with a step size of 0.5 mm and a resolution of 1024 Â 1024 pixels (0.37 mm/pixel). The number of RGC cell bodies was quantified in grids of 62 500 mm 2 at 1 mm and 1.5 mm from the optic disk. The density of surviving RGCs was represented in the individual quadrants or in the whole retina per mm 2 .
Staining of apoptotic neurons with Annexin V. To detect apoptotic neurons, 1.5 ml. of Annexin V conjugated to Cy3 (Apoptosis Detection Kit plus, BioVision Incorporated, Lausen, Switzerland, no. K202-100) was injected in the Neuronal Nogo-A modulates axonal regeneration V Pernet et al eye of axotomized animals, 2 h before perfusion. After fixation and immunostaining for Nogo-A and b3Tubulin, Annexin V-Cy3-positive cells were visualized on retinal flat-mounts at the peak of apoptosis, 7 days after injury. 23 Labelled cells were observed by confocal microscopy (see above).
Axonal regeneration analysis. To study axonal regeneration, the optic nerve was crushed intraorbitally. The optic nerve was fully constricted for 15 s by tying a knot with a 9-0 suture. The suture was then carefully removed and a fundus examination allowed to control the integrity of the ophthalmic artery. Thirteen days after optic nerve crush, the optic axons were anterogradely traced by injecting 1.5 ml of 0.5% cholera toxin b subunit conjugated to alexa 594 (CTb-594, Molecular Probes, Basel, Switzerland) into the vitreous space. The day after, the animals were perfused and the optic nerves were processed as described below. CTb-594-positive axons were observed on optic nerve longitudinal sections (14 mm) with a Zeiss Axioskop 2 Plus microscope (Carl Zeiss, Feldbach, Switzerland) and images were taken with a CCD video camera at Â 20. The number of growing axons was estimated at 100 mm, 250 mm, 500 mm and 1000 mm after the crush site as detailed before. 24 Optic nerve slices were examined in 3-6 animals per condition. An estimation of the number of axons per optic nerve (S) was calculated with the following formula: S d ¼ P Â R 2 Â (average number of axons/ mm)/T. The sum (S) of axons at a given distance (d) was obtained using the average optic nerve radius (R) of all optic nerves, and a thickness (T) of the tissue slices of 14 mm.
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For statistical analysis, an ANOVA followed by a Bonferroni's or Dunnett's post hoc test was applied for multiple comparisons. Animals presenting ischemia or retinal hemorrhages were excluded from the analysis.
Intraocular injections. AAV viruses, Pam3Cys or the anterograde tracer CTb-594 were injected intraocularly using a 10-ml Hamilton syringe adapted with a pulled-glass tip and as previously described. 24 To allow the diffusion of the viruses, the needle was kept in place for 3-4 min and then carefully removed. Attention was paid not to damage the lens or the ciliary bodies that were reported to stimulate growth. 8, 39 To up-or downregulate Nogo-A expression in RGCs, 2-4 ml of AAV2.Nogo-A or AAV2.shRNA-Nogo-A were injected intraocularly 4-6 weeks before optic nerve injury, a time necessary to obtain an optimal transgene expression in vivo. Similar volumes and concentrations of AAV2.GFP or AAV.shRNA-Luciferase were used as control vectors.
In some groups, axonal regeneration was activated by injecting in the vitreal chamber the toll-like receptor 2 agonist (S)-(2,3-Bis(palmitoyloxy)-(2-RS)-propyl)-Npalmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH (Pam3Cys, EMC Microcolections, Tübin-gen, Germany). Pam3Cys is a water soluble molecule that was previously shown to induce inflammation-mediated axonal regeneration in the rat optic nerve. 9 Two injections of Pam3Cys (2 ml, 2.5 mg/ml) were performed at the time of the optic nerve lesion and 7 days later.
Retina and optic nerve processing and immunostaining. Adult mice were killed by injecting an overdose of anesthetic intraperitoneally. After intracardiac perfusion with PBS (0.1 M) and 4% PFA, the eyes were rapidly dissected by removing the cornea and the lens. For retinal cross sections, the eye cups were postfixed in 4% PFA overnight at 4 1C. The tissues were then cryoprotected in 30% sucrose overnight and frozen in OCT compound (optimal cutting temperature, Tissue-TEK, Sakura, Alphen aan den Rijn, The Netherlands) with a liquid nitrogen-cooled bath of 2-methylbutane. Optic nerves and retinal sections were cut (14 mm) with a cryostat and collected on Superfrost Plus slides (Menzel-Glaser, Braunschweig, Germany). For immunohistochemistry procedure, tissue slices were blocked with 5% BSA or normal serum, 0.3% Triton X-100 in PBS for 1 h at room temperature to avoid unspecific cross-reactivity. Then, primary antibodies were applied in 5% BSA or normal serum, 0.3% Triton X-100 in PBS overnight at 4 1C. After PBS washes, sections were incubated with the appropriate secondary antibody for 1 h at room temperature, and mounted with MOWIOL anti-fading medium (10% Mowiol 4-88 (w/v) (Calbiochem), in 100 mM Tris, pH 8. 
Semi-quantitative RT-PCR (qRT-PCR).
After cervical dislocation, intact and injured whole retinae (WT, n ¼ 3 retinae; and Nogo-A KO, n ¼ 4 retinae) or dorsal hemi-retinae (AAV2-treated, n ¼ 3-4 retinae) were rapidly dissected in RNA Later solution (Ambion). The samples were placed in eppendorf tubes, flash frozen in liquid nitrogen and stored at À80 1C until RNA extraction. The RNeasy RNA isolation kit (Qiagen, Hilden, Germany) was used. Residual genomic DNA was digested by DNase treatment. For reverse transcription, the same amounts of total RNA were transformed by using oligo(dT) primers and M-MLV reverse transcriptase (Promega). The cDNAs corresponding to 10 ng of total RNA were amplified with the following specific primers designed to span intronic sequences or cover exon-intron boundaries: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward, 5 Gene expression was analyzed by real-time RT-PCR with a polymerase ready mix (Light Cycler480, SYBR Green I Master; Roche Diagnostics, Rotkreutz, Switzerland) and a thermocycler (LightCycler; Roche Diagnostics). The analysis of the melting curve of each amplified PCR product and the visualization of the PCR amplicons on 1.5% agarose gels allowed to control the specificity of the amplification. For relative quantification of gene expression, mRNA levels were normalized to GAPDH using the comparative threshold cycle (DD CT ) method. Similar normalized results were obtained by using b-actin as housekeeping gene. For calibration, a control sample was used to calculate the relative values. Each reaction was done in triplicate.
Western blot analysis. Three mice per group were killed by cerebral dislocation and retinae and optic nerves were quickly dissected out and flash frozen in liquid nitrogen. Tissues were kept at À80 1C until extraction in lysis buffer (20 mM Tris-HCl, 0.5% CHAPS, pH 8) containing protease inhibitors (Complete mini, Roche diagnostics). The samples were fully homogenized and let on ice for 60 min. After centrifugation for 15 min at 15 000 Â g, 4 1C, the supernatant was collected in new eppendorf tubes, and stored at À80 1C. Proteins (20 mg/lane) were separated by electrophoresis on a 4-12% polyacrylamide gel and transferred to nitrocellulose membranes. Blots were pre-incubated in a blocking solution of 2% Top Block (Lubio Science, Lucerne, Switzerland) in TBST 0.2% (Tris-base 0.1 M, 0.2% Tween-20, pH7.4) for 1 h at room temperature, incubated with primary antibodies overnight at 4 1C and after washing, with a horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (1 : 10 000-1 : 25 000; Pierce Biotechnology, Lausanne, Switzerland). Primary antibodies were rabbit anti-Nogo-A/B (Bianca, Rb1 40 ) serum (1 : 20 000), rabbit anti-CHOP/GADD153 (1 : 100, Santa Cruz Biotechnology, no. sc-575) and mouse anti-GAPDH (1 : 10 000; Abcam, Cambridge, UK).
Protein bands were detected by adding SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology) and after exposure of the blot in a Stella detector. The quantification of the band intensity was done with the Image J software (NIH, Bethesda, MD, USA).
Cell cultures. Freshly dissociated Müller cells were prepared from C57BL/6 adult mouse retinae (3-4 month old). In brief, retinae were rapidly isolated in CO 2 -independent medium after cervical dislocation. After two washes in Ringer solution, the retinae were incubated for 35 min at 37 1C in a digestion solution containing 1.5 mg/ml of papain and 12.5 mM of L-cystein dissolved in Ringer buffer. The retinae were then gently triturated in a solution of Dulbecco'S modified Eagle's medium (DMEM) with 10% FBS, 0.1 mg/ml DNase I using a fire-polished Pasteur pipette. The cell suspension was then centrifuged at 250 Â g for 3 min and washed twice with medium. At the last centrifugation, the cell pellet was re-suspended in B1 ml of medium and cells were seeded on poly-D-lysine/laminin-coated glass coverslips. For immunofluorescence, B1 h after cell adhesion, the cells were fixed with 4% PFA for 30 min, rinsed three times with PBS and incubated for 1 h at room temperature in a blocking solution (0.1 M PBS; 0.1% triton-X100; 5% normal goat serum). The rabbit anti-Nogo-A antibody Laura (1 : 200) and the mouse anti-GS antibody (1 : 400) were then added overnight at 4 1C. After washes and secondary antibody incubation the stained cells were imaged with a confocal microscope as described for tissue sections.
The efficacy of AAV.shRNA-Nogo-A to downregulate Nogo-A protein expression was tested on the RGC-5 cell line 41 (a gift from Dr. Krishnamoorthy, Fort Worth, TX, USA) by western blotting. One ml of AAV8.shRNA-Nogo-A or AAV8.GFP control virus (1.3 Â 10 13 vg/ml) was added to RGC-5 cells plated at a density of 200 000 cells/ml in 6-well plates, in serum-free DMEM. Five days later, RGC-5 cells were lysed with CHAPS buffer and proteins were separated by electrophoresis as described above.
The effects of AAV2.Nogo-A, AAV8.shRNA-Nogo-A, AAV2.GFP and AAV8.GFP on neurite outgrowth were evaluated in vitro by infecting F11 cells. The F11 cell line, kindly provided by Prof. RE van Kesteren (Amsterdam, The Netherlands), was maintained as described before.
42 F11 cells were plated at a density of 100 000 cells per well in 6-well plates and were treated with AAV viruses 24 h later. Four days after infection, F11 cells were transferred to 4-well dishes at a density of 2000 cells per well. Twenty four hours after cell spreading, F11 cells were differentiated by adding 10 mM of forskolin for 48 h. To visualize neurite extension, F11 cells were co-immunostained for b3Tubulin and GFP or His-tag to observe the cells infected with AAV2.GFP/AAV8.GFP/AAV8.shRNA-Nogo-A or AAV2.Nogo-A, respectively. In three independent experiments, the measurement of neurite length was carried out using the Neuron J plugin in the Image J software (NIH). The mean of the total neurite length was calculated for the different treatments using between 318 and 466 cells which neurite length Z25 mm. The level of GFP (AAV2.GFP/AAV8.GFP or AAV8.shRNA-Nogo-A), His peptide (AAV2.Nogo-A) and Nogo-A expressions were assessed in F11 cells bodies by densitometry in Image J.
